Immuno-oncology platform focused on cell therapy
Aleta’s proprietary CAR-T Engager technology incorporates potent multi-antigen targeting with optimal CAR-T cell fitness and persistence to attack aggressively cancers.
Aleta’s Engager technology can potentially address clinical issues ranging from cell therapy relapse due to antigen loss to overcoming solid tumour heterogeneity. Aleta’s lead program will enter Phase I/II trials in 2023 in collaboration with Cancer Research UK.
CEO Paul Rennert (Founder and CSO)